--- title: "InnoCore Pharmaceuticals Announces New Collaboration with U.S. Biotech Partner Focused on Metabolic Disease" id: "1779" type: "post" slug: "innocore-pharmaceuticals-announces-new-collaboration-with-u-s-biotech-partner-focused-on-metabolic-disease" published_at: "2025-07-15T11:29:00+00:00" modified_at: "2025-11-24T12:32:55+00:00" url: "https://innocorepharma.com/news-events/innocore-pharmaceuticals-announces-new-collaboration-with-u-s-biotech-partner-focused-on-metabolic-disease/" markdown_url: "https://innocorepharma.com/news-events/innocore-pharmaceuticals-announces-new-collaboration-with-u-s-biotech-partner-focused-on-metabolic-disease.md" taxonomy_category: - "Latest News" --- 15 July 2025 | Latest News # InnoCore Pharmaceuticals Announces New Collaboration with U.S. Biotech Partner Focused on Metabolic Disease # **InnoCore Pharmaceuticals Announces New Collaboration with U.S. Biotech Partner Focused on Metabolic Disease** - ***Two new peptide formulation projects aim to harness the SynBiosys® platform to advance obesity and metabolic treatments*** **Groningen, The Netherlands – 15 July 2025** – InnoCore Pharmaceuticals (“InnoCore”), a leading specialist in long-acting injectable (LAI) drug delivery technologies, today announced a new partnership with a U.S.-based biotechnology company developing next-generation GLP-1 therapies for obesity and metabolic diseases. The agreement covers two distinct peptide formulation projects, both utilizing InnoCore’s proprietary SynBiosys® technology, a best-in-class biodegradable polymeric platform designed for long acting injectable drug delivery. The collaboration marks the start of a new strategic partnership and underscores InnoCore’s growing role as a key innovation partner in the formulation of biologics and peptides dosage forms to biotech and pharmaceutical companies worldwide. Building on its growth strategy, InnoCore continues to expand its market presence in the biologics and peptide-based LAI sector, a multi-billion dollar segment seeing rapid expansion as demand for sustained-release biologic and peptide therapies accelerates globally for the treatment of chronic diseases, including obesity and cardiometabolic disease. SynBiosys® enables the development of precisely tuned, sustained-release peptide formulations that maintain biological activity and stability while offering controlled release periods ranging from weeks to months. The platform’s biodegradable and tunable polymer composition overcomes the technical barriers that typically limit peptide formulation, such as enzymatic degradation and structural instability. The projects significantly contribute to the strength of the competitive position of the partner’s product portfolio. **Bart-Jan Korteling, Chief Operating Officer at InnoCore Pharmaceuticals,** commented: *“We’re delighted to welcome this innovative U.S. biotech company as a new customer. This client is working at the forefront of developing metabolic disease therapeutics and their expertise and approach in this field align perfectly with our mission, to translate complex peptide molecules into stable, scalable, and patient-friendly long-acting injectables. These two new projects not only validate our SynBiosys® platform’s versatility but also reflect our growing global footprint as a trusted formulation partner for biologics and peptides, achieving strategic key goals for our clients.”* With over 20 years of formulation and process development expertise, InnoCore provides full in-house capabilities for polymer synthesis, analytical characterization, and scalable process development from feasibility to clinical manufacture. Its state-of-the-art facilities and multi-disciplinary scientific team allow rapid translation of challenging APIs, especially peptides and biologics, into high-performance, long-acting injectable dosage forms. -Ends- **For more information, please contact:** | InnoCore Pharmaceuticals | Contact details | | --- | --- | | Bart-Jan Korteling, COO Martin Bakker, CBO | [email protected] Tel: +31 50 575 3100 | | | | | Vigo Consulting | | | Melanie Toyne-Sewell Rozi Morris | [email protected] Tel: +44 7390 0230 | **Notes to Editors** **About InnoCore Pharmaceuticals** InnoCore Pharmaceuticals is a leading drug delivery development provider, formulating peptide and biologic APIs into scalable, biodegradable and tunable Long Acting Injectable (LAI) dosage forms. The Company’s proprietary polymeric drug delivery platform, SynBiosys®, overcomes the significant technical challenges of translating these complex and fragile molecules into LAI drug products that maintain their essential bioactive characteristics. Dosage forms can be created for early proof of concept, through to clinical trial usage in an easy-to-scale cGMP form. These formulations can be adapted for use in local or systematic injectable forms for a wide range of therapeutic applications, such as osteoarthritis, rheumatology, oncology, CNS, infectious and cardiometabolic diseases. InnoCore is a true strategic partner to its biopharma customers working hand-in-hand with them to lay strong foundations for future clinical and commercial success. InnoCore is innovating biologic drug formulation for better treatment outcomes and compliance. For more information, please see: [www.innocorepharma.com](http://www.innocorepharma.com) . Related insights [26 July 2018 | Funding InnoCore and Merck enter global collaboration Merck and InnoCore Pharmaceuticals to Improve Patient Compliance with New Drug Delivery Technology. Read the full story](https://innocorepharma.com/news-events/innocore-and-merck-enter-global-collaboration/) [11 September 2020 | Funding Bill & Melinda Gates Foundation Grant Awarded InnoCore Pharmaceuticals has been awarded a grant by the Bill & Melinda Gates Foundation to develop a long-acting injectable contraceptive implant. Read the full story](https://innocorepharma.com/news-events/innocore-awarded-grant-by-the-bill-melinda-gates-foundation-in-contraception/) [01 January 2021 | Funding InnoCore leads Consortium in Influenza vaccines InnoCore Pharmaceuticals has secured funding from the European Regional Development Fund to develop a biodegradable polymer-based microneedle array patch. Read the full story](https://innocorepharma.com/news-events/innocore-leads-consortium-in-influenza-vaccines/)